
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Aptorum Group Ltd Class A (APM)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: APM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -88.87% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.07M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 71767 | Beta -0.32 | 52 Weeks Range 0.46 - 5.05 | Updated Date 06/17/2025 |
52 Weeks Range 0.46 - 5.05 | Updated Date 06/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.33% | Return on Equity (TTM) -30.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10553113 | Price to Sales(TTM) 23.35 |
Enterprise Value 10553113 | Price to Sales(TTM) 23.35 | ||
Enterprise Value to Revenue 31.22 | Enterprise Value to EBITDA -0.45 | Shares Outstanding 5346820 | Shares Floating 3404715 |
Shares Outstanding 5346820 | Shares Floating 3404715 | ||
Percent Insiders 19.48 | Percent Institutions 1.76 |
Analyst Ratings
Rating 4.5 | Target Price 115 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aptorum Group Ltd Class A
Company Overview
History and Background
Aptorum Group Limited was incorporated in 2016 and is based in Hong Kong. It is a pharmaceutical company focused on developing and commercializing novel therapeutics to tackle unmet medical needs.
Core Business Areas
- Pharmaceutical Development: Focuses on identifying, developing, and commercializing therapeutic products for various diseases.
- Infectious Disease Diagnostics: Develops rapid and accurate diagnostic tools for infectious diseases.
- Women's Health: Develops new therapies for women's health disorders.
Leadership and Structure
Ian Huen is the Chief Executive Officer and Executive Director. The organizational structure involves a board of directors and various management teams overseeing different business segments.
Top Products and Market Share
Key Offerings
- SACT-1: A repurposed small molecule drug for Staphylococcus aureus infections. Early-stage clinical trials. Market share is not yet applicable as it is in development. Competitors include companies that produce antibiotics such as Pfizer, Merck, and GlaxoSmithKline.
- RPIDD: Rapid pathogen identification and detection diagnostics. Market share is not yet applicable as it is in development. Competitors include Roche, Abbott, and Thermo Fisher Scientific.
- ALS-4: A small molecule drug for neuroblastoma. Early-stage preclinical studies. Market share is not yet applicable as it is in development. Competitors include companies that develop cancer therapies such as Novartis, Bristol Myers Squibb, and Johnson & Johnson.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with increasing demand for novel therapeutics and diagnostics. Growth is driven by aging populations and increasing prevalence of chronic diseases.
Positioning
Aptorum Group is positioned as a developer of innovative therapeutics and diagnostics, focusing on unmet medical needs. Its competitive advantage lies in its proprietary technology platforms and focus on specific disease areas.
Total Addressable Market (TAM)
The total addressable market varies significantly depending on the specific disease area and geographic region. Aptorum Group's positioning within this TAM is focused on niche segments with high growth potential but faces significant regulatory hurdles and competition.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Focus on unmet medical needs
- Experienced management team
- Diversified product pipeline
Weaknesses
- Limited financial resources
- Early-stage product pipeline
- Dependence on partnerships and collaborations
- Geographic concentration in Hong Kong/Asia
Opportunities
- Expanding into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Regulatory approvals for key products
- Increasing demand for personalized medicine
Threats
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies
- Patent infringement
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
Competitive Landscape
Aptorum faces intense competition from larger, more established pharmaceutical companies with greater resources. Its advantage lies in its innovative technology and focus on specific disease areas, but it needs to secure partnerships and funding to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the early stage of the company's product pipeline.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary widely, reflecting the inherent uncertainty.
Recent Initiatives: Recent initiatives include advancing key product candidates into clinical trials and securing partnerships with research institutions.
Summary
Aptorum Group is an early-stage pharmaceutical company focusing on unmet medical needs with innovative technology. Its financial stability is questionable, as it is dependent on clinical trials. The company's strong focus on specific diseases is working well, but its lack of financial resources and intense competition need to be carefully monitored. Aptorum Group must secure more funding and form strategic partnerships to thrive in the long term.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- SEC.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on available data and current market conditions, which are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptorum Group Ltd Class A
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-12-18 | Founder, CEO & Executive Director Mr. Chung Yuen Huen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.aptorumgroup.com |
Full time employees 1 | Website https://www.aptorumgroup.com |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.